Kazuhiro Tsuruma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kazuhiro Tsuruma has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hideaki Hara
Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University
7 shared publications - Masamitsu Shimazawa
Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan
5 shared publications - Yuta Ohno
Department of Pharmacology, Asahi University School of Dentistry, 1851-1 Hozumi, Mizuho, Gifu 501-0296, Japan
2 shared publications Atsushi Oyagi
Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan
1 shared publication- Hideki Ito
Department of Cardiac Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication - Hideo Kaneko
Department of Pediatric Medical Care, Gifu Prefectural General Medical Center, Gifu, Japan
1 shared publication
Latest Publications
- 1 February 2018
- Published by Elsevier in Experimental Eye Research
- Vol. 167, 44-50
Involvement of cannabinoid receptor type 2 in light-induced degeneration of cells from mouse retinal cell line in vitro and mouse photoreceptors in vivo
- 1 February 2018
- Published by Elsevier in Experimental Eye Research
- Vol. 167, 44-50
Involvement of cannabinoid receptor type 2 in light-induced degeneration of cells from mouse retinal cell line in vitro and mouse photoreceptors in vivo
- Open Access
- 11 October 2017
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 729
Overcoming Obstacles to Drug Repositioning in Japan
Drug repositioning (DR) is the process of identifying new indications for existing drugs. DR usually focuses on drugs that have cleared phase-I safety trials but has yet to show efficacy for the intended indication. Therefore, DR can probably skip the preclinical and phase-I study, which can reduce the cost throughout drug development. However, the expensive phase-II/III trials are required to establish efficacy. The obstacles to DR include identification of new indications with a high success rate in clinical studies, obtaining funding for clinical studies, patent protection, and approval systems. To tackle these obstacles, various approaches have been applied to DR worldwide. In this perspective, we provide representative examples of DR and discuss the ongoing efforts to overcome obstacles to DR in Japan.
- 11 October 2017
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 729
Open AccessOvercoming Obstacles to Drug Repositioning in Japan
Drug repositioning (DR) is the process of identifying new indications for existing drugs. DR usually focuses on drugs that have cleared phase-I safety trials but has yet to show efficacy for the intended indication. Therefore, DR can probably skip the preclinical and phase-I study, which can reduce the cost throughout drug development. However, the expensive phase-II/III trials are required to establish efficacy. The obstacles to DR include identification of new indications with a high success rate in clinical studies, obtaining funding for clinical studies, patent protection, and approval systems. To tackle these obstacles, various approaches have been applied to DR worldwide. In this perspective, we provide representative examples of DR and discuss the ongoing efforts to overcome obstacles to DR in Japan.
- 16 May 2017
- Published by Wiley in Journal of Neuroscience Research
- Vol. 95 (12) , 2500-2510
Progranulin increases phagocytosis by retinal pigment epithelial cells in culture
Retinal pigment epithelium (RPE) cells take part in retinal preservation, such as phagocytizing the shed photoreceptor outer segments (POS), every day. The incomplete phagocytic function accelerates RPE degeneration and formation of the toxic by‐product lipofuscin. Excessive lipofuscin accumulation is characteristic of various blinding diseases in the human eye. Progranulin is a cysteine‐rich protein that has multiple biological activities, and it has a high presence in the retina. Progranulin has been recognized to be involved in macrophage phagocytosis in the brain. The purpose of this study is to determine whether progranulin influences phagocytosis by RPE cells. All experiments were performed on primary human RPE (hRPE) cells in culture. pHrodo was used to label the isolated porcine POS, and quantification of pHrodo fluorescence was used to determine the degree of phagocytosis. Western blotting and immunohistochemistry of key proteins involved in phagocytosis were used to clarify the mechanism of progranulin. Progranulin increased RPE phagocytosis in hydrogen peroxide–treated and nontreated RPE cells. The phosphorylated form of Mer tyrosine kinase, which is important for POS internalization, was significantly increased in the progranulin‐exposed cells. This increase was attenuated by SU11274, an inhibitor of hepatic growth factor receptor. Under the oxidative stress condition, exposure to progranulin led to an approximately twofold increase in integrin alpha‐v, which is associated with the first step in recognition of POS by RPE cells. These results suggest that progranulin could be an effective stimulator for RPE phagocytosis and could repair RPE function.
- 16 May 2017
- Published by Wiley in Journal of Neuroscience Research
- Vol. 95 (12) , 2500-2510
Progranulin increases phagocytosis by retinal pigment epithelial cells in culture
Retinal pigment epithelium (RPE) cells take part in retinal preservation, such as phagocytizing the shed photoreceptor outer segments (POS), every day. The incomplete phagocytic function accelerates RPE degeneration and formation of the toxic by‐product lipofuscin. Excessive lipofuscin accumulation is characteristic of various blinding diseases in the human eye. Progranulin is a cysteine‐rich protein that has multiple biological activities, and it has a high presence in the retina. Progranulin has been recognized to be involved in macrophage phagocytosis in the brain. The purpose of this study is to determine whether progranulin influences phagocytosis by RPE cells. All experiments were performed on primary human RPE (hRPE) cells in culture. pHrodo was used to label the isolated porcine POS, and quantification of pHrodo fluorescence was used to determine the degree of phagocytosis. Western blotting and immunohistochemistry of key proteins involved in phagocytosis were used to clarify the mechanism of progranulin. Progranulin increased RPE phagocytosis in hydrogen peroxide–treated and nontreated RPE cells. The phosphorylated form of Mer tyrosine kinase, which is important for POS internalization, was significantly increased in the progranulin‐exposed cells. This increase was attenuated by SU11274, an inhibitor of hepatic growth factor receptor. Under the oxidative stress condition, exposure to progranulin led to an approximately twofold increase in integrin alpha‐v, which is associated with the first step in recognition of POS by RPE cells. These results suggest that progranulin could be an effective stimulator for RPE phagocytosis and could repair RPE function.
- Open Access
- 31 March 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 23811
Progranulin promotes the retinal precursor cell proliferation and the photoreceptor differentiation in the mouse retina
Progranulin (PGRN) is a secreted growth factor associated with embryo development, tissue repair and inflammation. In a previous study, we showed that adipose-derived stem cell-conditioned medium (ASC-CM) is rich in PGRN. In the present study, we investigated whether PGRN is associated with retinal regeneration in the mammalian retina. We evaluated the effect of ASC-CM using the N-methyl-N-nitrosourea-induced retinal damage model in mice. ASC-CM promoted the differentiation of photoreceptor cells following retinal damage. PGRN increased the number of BrdU+ cells in the outer nuclear layer following retinal damage some of which were Rx (retinal precursor cell marker) positive. PGRN also increased the number of rhodopsin+ photoreceptor cells in primary retinal cell cultures. SU11274, a hepatocyte growth factor (HGF) receptor inhibitor, attenuated the increase. These findings suggest that PGRN may affect the differentiation of retinal precursor cells to photoreceptor cells through the HGF receptor signaling pathway.
- 31 March 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 23811
Open AccessProgranulin promotes the retinal precursor cell proliferation and the photoreceptor differentiation in the mouse retina
Progranulin (PGRN) is a secreted growth factor associated with embryo development, tissue repair and inflammation. In a previous study, we showed that adipose-derived stem cell-conditioned medium (ASC-CM) is rich in PGRN. In the present study, we investigated whether PGRN is associated with retinal regeneration in the mammalian retina. We evaluated the effect of ASC-CM using the N-methyl-N-nitrosourea-induced retinal damage model in mice. ASC-CM promoted the differentiation of photoreceptor cells following retinal damage. PGRN increased the number of BrdU+ cells in the outer nuclear layer following retinal damage some of which were Rx (retinal precursor cell marker) positive. PGRN also increased the number of rhodopsin+ photoreceptor cells in primary retinal cell cultures. SU11274, a hepatocyte growth factor (HGF) receptor inhibitor, attenuated the increase. These findings suggest that PGRN may affect the differentiation of retinal precursor cells to photoreceptor cells through the HGF receptor signaling pathway.
- 23 February 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 260 (7) , 1782-1797
ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis
The diagnosis of amyotrophic lateral sclerosis (ALS) is difficult due to lack of definitive biomarkers. Our aim was to identify characteristic serum protein patterns that could provide candidate biomarkers for ALS. We divided mutant superoxide dismutase-1 (SOD1)H46R rats into three groups based on disease progression: pre-symptom (90 days), onset, and end-stage. After separation of serum proteins using two-dimensional electrophoresis, we selected clear protein spots and identified two candidate proteins—inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) and glutathione peroxidase 3 (Gpx3). The 120 kDa ITIH4 increased at the onset of the disease and the 85 kDa ITIH4, a cleaved form, at the end-stage in the sera of the SOD1H46R rats. Expression of the 85 kDa ITIH4 was substantial in ALS compared with controls or patients with muscular dystrophy, Alzheimer diseases, or Parkinson diseases. The Gpx3 protein levels in the sera of SOD1H46R rats were upregulated pre-symptom and gradually decreased as the disease progressed. The Gpx3 protein levels were lower in the sera of the patients with ALS than in other diseases. These results indicate that ITIH4 and Gpx3 are potential biomarkers for ALS.
- 23 February 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 260 (7) , 1782-1797
ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis
The diagnosis of amyotrophic lateral sclerosis (ALS) is difficult due to lack of definitive biomarkers. Our aim was to identify characteristic serum protein patterns that could provide candidate biomarkers for ALS. We divided mutant superoxide dismutase-1 (SOD1)H46R rats into three groups based on disease progression: pre-symptom (90 days), onset, and end-stage. After separation of serum proteins using two-dimensional electrophoresis, we selected clear protein spots and identified two candidate proteins—inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) and glutathione peroxidase 3 (Gpx3). The 120 kDa ITIH4 increased at the onset of the disease and the 85 kDa ITIH4, a cleaved form, at the end-stage in the sera of the SOD1H46R rats. Expression of the 85 kDa ITIH4 was substantial in ALS compared with controls or patients with muscular dystrophy, Alzheimer diseases, or Parkinson diseases. The Gpx3 protein levels in the sera of SOD1H46R rats were upregulated pre-symptom and gradually decreased as the disease progressed. The Gpx3 protein levels were lower in the sera of the patients with ALS than in other diseases. These results indicate that ITIH4 and Gpx3 are potential biomarkers for ALS.
- 29 July 2011
- Published by Wiley in Journal of Neuroscience Research
- Vol. 89 (11) , 1783-1794
Involvement of Bid and caspase‐2 in endoplasmic reticulum stress‐ and oxidative stress‐induced retinal ganglion cell death
Endoplasmic reticulum (ER) stress and oxidative stress are involved in many diseases, including retinal disorders, causing toxicity in various tissues and cells; however, intracellular signaling of ER stress and cross‐talk between ER stress and oxidative stress are unknown in retinal ganglion cells (RGC), whose degeneration is associated with glaucoma. The aim of the study was to clarify the mechanisms of ER stress‐ and oxidative stress‐induced RGC death, using cultured retinal ganglion cells (RGC‐5) in vitro and N‐methyl‐D‐aspartate (NMDA)‐ or ER stress‐induced retinal damage in mice in vivo. We focused on both BH3‐interacting domain death agonist (Bid) and caspase‐2, which work as apoptosis promotion factors. In an in vitro study, both Bid and caspase‐2 inhibitors protected against RGC‐5 death from ER stress or oxidative stress. A caspase‐2 inhibitor did not inhibit Bid cleavage, although a Bid inhibitor reduced the increase of caspase‐2 activity in ER stress‐induced RGC‐5 death. A Bid inhibitor also reduced the increase of caspase‐2 activity in oxidative stress‐induced RGC‐5 death. Moreover, both Bid and caspase‐2 inhibitors reduced the increase of caspase‐3 activity. In an in vivo study, a Bid inhibitor inhibited NMDA‐ or ER stress‐induced retinal damage. These findings indicate that a common mechanism through Bid and caspase‐2 existsin both ER stress‐ and oxidative stress‐induced RGC death and that they are activated in the order of Bid, caspase‐2, and caspase‐3.
- 29 July 2011
- Published by Wiley in Journal of Neuroscience Research
- Vol. 89 (11) , 1783-1794
Involvement of Bid and caspase‐2 in endoplasmic reticulum stress‐ and oxidative stress‐induced retinal ganglion cell death
Endoplasmic reticulum (ER) stress and oxidative stress are involved in many diseases, including retinal disorders, causing toxicity in various tissues and cells; however, intracellular signaling of ER stress and cross‐talk between ER stress and oxidative stress are unknown in retinal ganglion cells (RGC), whose degeneration is associated with glaucoma. The aim of the study was to clarify the mechanisms of ER stress‐ and oxidative stress‐induced RGC death, using cultured retinal ganglion cells (RGC‐5) in vitro and N‐methyl‐D‐aspartate (NMDA)‐ or ER stress‐induced retinal damage in mice in vivo. We focused on both BH3‐interacting domain death agonist (Bid) and caspase‐2, which work as apoptosis promotion factors. In an in vitro study, both Bid and caspase‐2 inhibitors protected against RGC‐5 death from ER stress or oxidative stress. A caspase‐2 inhibitor did not inhibit Bid cleavage, although a Bid inhibitor reduced the increase of caspase‐2 activity in ER stress‐induced RGC‐5 death. A Bid inhibitor also reduced the increase of caspase‐2 activity in oxidative stress‐induced RGC‐5 death. Moreover, both Bid and caspase‐2 inhibitors reduced the increase of caspase‐3 activity. In an in vivo study, a Bid inhibitor inhibited NMDA‐ or ER stress‐induced retinal damage. These findings indicate that a common mechanism through Bid and caspase‐2 existsin both ER stress‐ and oxidative stress‐induced RGC death and that they are activated in the order of Bid, caspase‐2, and caspase‐3.
- 11 November 2010
- Published by Wiley in BioFactors
- Vol. 37 (1) , 25-30
The antianxiety‐like effect of astaxanthin extracted from Paracoccus carotinifaciens
Astaxanthin is a red carotenoid pigment and is widely found in living organisms. Astaxanthin has a potent antioxidative ability and has been reported as having various biological effects on the central nerve system, such as a protective effect against ischemia/reperfusion injury and improvement in cognitive function. In this study, to investigate the effects of astaxanthin on anxiety and depression, we performed some behavioral trials including the elevated plus maze test, hole-board test, forced swim test, and tail suspension test. Astaxanthin (100 and 300 mg/kg/day for 10 days, p.o.) significantly increased the time spent in open arms in the elevated plus maze test and increased the head-dipping count and duration in the hole-board test. On the other hand, astaxanthin (10, 100, 300, and 500 mg/kg/day for 10 days, p.o.) did not change the immobility time in the forced swim test or the tail suspension test. In conclusion, in mice, astaxanthin exerted anxiolytic-like effects, but not antidepressant-like effects.
- 11 November 2010
- Published by Wiley in BioFactors
- Vol. 37 (1) , 25-30
The antianxiety‐like effect of astaxanthin extracted from Paracoccus carotinifaciens
Astaxanthin is a red carotenoid pigment and is widely found in living organisms. Astaxanthin has a potent antioxidative ability and has been reported as having various biological effects on the central nerve system, such as a protective effect against ischemia/reperfusion injury and improvement in cognitive function. In this study, to investigate the effects of astaxanthin on anxiety and depression, we performed some behavioral trials including the elevated plus maze test, hole-board test, forced swim test, and tail suspension test. Astaxanthin (100 and 300 mg/kg/day for 10 days, p.o.) significantly increased the time spent in open arms in the elevated plus maze test and increased the head-dipping count and duration in the hole-board test. On the other hand, astaxanthin (10, 100, 300, and 500 mg/kg/day for 10 days, p.o.) did not change the immobility time in the forced swim test or the tail suspension test. In conclusion, in mice, astaxanthin exerted anxiolytic-like effects, but not antidepressant-like effects.